CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), has received the ‘Most Impactful Industry Collaboration of the Year’ at the 2023 OBN Awards. The award recognises the ongoing success of the Company’s…
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced strong topline results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib compared with placebo plus ruxolitinib in JAK inhibitor-naïve patients with…
Prospection—the pioneer of patient-centric intelligence—today announced the availability of Prospection AI, its self-service patient-centric intelligence (PCI) platform designed to save life sciences commercial organizations time and money by unlocking insights into the complete patient care journey to achieve full market potential…
Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced positive results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of…
The PACIFIC-2 Phase III trial for Imfinzi (durvalumab) concurrently administered with chemoradiotherapy (CRT) did not achieve statistical significance for the primary endpoint of progression-free survival (PFS) versus CRT alone for the treatment of patients with unresectable, Stage III non-small cell lung cancer…
Bayer and Recursion focus research collaboration on Oncology Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that they have updated the focus of their research collaboration to precision oncology.…
AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023 Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early oligoarticular psoriatic arthritis. FOREMOST is the first placebo-controlled study designed to specifically assess people with oligoarticular psoriatic…
Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today…
Janssen Highlights Latest Research for TREMFYA® (guselkumab) and Investigational Targeted Oral Peptide JNJ-2113 in Moderate to Severe Plaque Psoriasis at the European Academy of Dermatology and Venereology (EADV) Congress Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, today announced that 30…
Thermo Fisher Scientific Expands St. Louis Manufacturing for Complex Biologic Treatments Thermo Fisher Scientific, the world leader in serving science, today expanded its manufacturing capacity in St. Louis to support biologic therapies for diseases ranging from cancers to auto immune…
A suit of armor for cancer-fighting cells In recent years, cancer researchers have hailed the arrival of chimeric antigen receptor T cell (CAR T) therapy, which has delivered promising results, transforming the fight against various forms of cancer. The process…
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets Boehringer Ingelheim, a leading research-driven biopharmaceutical company, said on Thursday it is well on track to achieve its 2030 emission reduction targets, and that it had received approval of those targets…